Male BRCA mutation carriers: clinical characteristics and cancer spectrum

BMC Cancer

Table 3 Cancer characteristics of male BRCA mutation carriers with breast cancer

ID	BRCA Gene	Mutation	Age at diagnosis	Size (cm)	LN	Stage	TNM stage	Grade	ER %	PR %	HER-2	Surgery	Chemo	RT	Status	F/U (yrs)
4	2	c.100G > T	75	1.4	neg	I	T1N0M0	2	92	18	pos	M	Yes, Trastuzumab	no	Alive, NED	5.7
8	2	c.736del20	52	N.A	N.A	N.A	N.A	3	97	87	Border-line	M	yes, TCH	yes	Alive	5.6
3	2	c.1813dupA	58	1.3	pos	II	T2N1M0	3	59	50	neg	M	yes, AC	yes	Expired	15.8
5	2	c.2808del4	67	1.7	pos	III	T1N3M0	3	100	89	pos	M	yes, ACTH	yes	Alive, NED	3.4
1	2	c.2808del4	68	1.6	pos	II	T2N1M0	3	90	40	neg	M	Yes, AC-T	yes	Alive, NED	7.0
7	2	c.5946del T	62	N.A	pos	II	N.A	3	90	N.A	N.A	M	Yes,CMF	yes	Alive, NED	21.0
9	2	c.5946delT	67	N.A	N.A	N.A	N.A	N.A	N.A	N.A	N.A	N.A	N.A	N.A	N.A	N.A
2	2	c.6676_6677delGA	62	2.5	pos	II	T2N1M0	2	100	37	pos	M	yes, TCHP	no	Alive, NED	1.8
6	2	c.6333_6337delGAGAA	68	6.0	pos	III	T4N2M0	3	97	29	neg	M	N.A	N.A	Expired	2.3

LN lymph node status, RT radiation therapy, M mastectomy, AC-T Doxorubicin, Cyclophosphamide and Paclitaxel, TCHP Docetaxel, Carboplatin, Trastuzumab and Pertuzumab, AC Doxorubicin and Cyclophosphamide, ACTH Doxorubicin, Cyclophosphamide, Paclitaxel and Trastuzumab, CMF Cyclophosphamide, Methotrexate and Fluorouracil, TCH Docetaxel, Carboplatin and Trastuzumab, NED no evidence of disease, F/U follow-up, NA not available, neg negative, pos positive

ISSN: 1471-2407